The greatest benefit was seen in patients with a BRCA1 and/or BRCA2 mutation or in the homologous recombination deficiency (HRD)-test positive subgroup. This evidence concerns the gene BRCA1 and hypoparathyroidism-retardation-dysmorphism syndrome.